Jonathan G Drachman MD

Physician

825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-288-1000

Join Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting!
Read the latest clinical news, personalized to your specialty.

Join Doximity Already have an account?

Summary

Dr. Jonathan Drachman, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington.

Education & Training

University of WashingtonFellowship, Medical Oncology, 1992 - 1994
Harvard Medical SchoolClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

WA State Medical License 1991 - 2025

Publications & Presentations

PubMed

31 citations
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cycloph...
Luis Fayad, Stephen M. Ansell, Ranjana H. Advani, Bertrand Coiffier, Robert K. Stuart
Leukemia & Lymphoma. 2015-02-04
83 citations
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos, Andres Forero-Torres, Stephen M. Ansell, Brad S. Kahl, Bruce D. Cheson
Journal of Hematology & Oncology. 2014-06-12
25 citations
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer
Jonathan G. Drachman, Peter D. Senter
Hematology. American Society of Hematology. Education Program. 2013-12-06

Press Mentions

StockWatch: Moderna Looks to Accelerate Cancer VaccineMarch 13th, 2023
Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of ResearchSeptember 9th, 2021
Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth ConferenceAugust 4th, 2021